drugset / Trial / NCT06453902
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Phase 2
Recruiting
40 enrolled
Shenzhen TargetRx Co., Ltd.
Chinese Academy of Medical Sciences · collabFirst Affiliated Hospital of Zhejiang University · collabHenan Cancer Hospital · collabHuazhong University of Science and Technology · collabNanfang Hospital, Southern Medical University · collabPeking University People's Hospital · collabRuijin Hospital · collabShengjing Hospital · collabShenzhen Second People's Hospital · collabThe First Affiliated Hospital of Soochow University · collab
NaSingle-groupOpen-labelTreatment
Summary
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment
Timeline
- Start
- 2024-07-15
- Primary completion
- 2026-06-30
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TGRX-678 | Unknown | 240 mg | Oral |